澳门葡京网赌游戏将收购Amolyt制药
扩大晚期罕见病治疗渠道

本新闻稿适用于财经媒体和投资者

Amolyt开发组合包括有潜力解决的三期资产
慢性甲状旁腺功能减退患者的显著未满足需求

此次收购将进一步扩大澳门葡京网赌游戏罕见病产品线
补体抑制，建立在公司在骨代谢和
难得的内分泌学机会
 

澳门葡京网赌游戏宣布已达成收购Amolyt制药的最终协议, 一家临床阶段的生物技术公司，专注于开发罕见内分泌疾病的新疗法.

拟议中的收购将支持Alexion, 澳门葡京网赌游戏罕见病 late-stage pipeline and expand on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. 此外，Alexion期待着来自Amolyt制药的人才.

甲状旁腺功能减退症患者, 甲状旁腺激素(PTH)的缺乏导致钙和磷酸盐的显著失调, 哪些会导致改变生活的症状和并发症, 包括慢性肾脏疾病.¹ 它是已知的最大的罕见病之一, 估计有115人受到影响,在美国有1000人死亡，107人死亡,000人在欧盟, 其中大约80%是女性.^2,3

Marc Dunoyer, 首席执行官, Alexion, 澳门葡京网赌游戏罕见病, 他说:“慢性甲状旁腺功能低下患者迫切需要一种替代现有支持性治疗的方法, 哪些不能解决潜在的激素缺乏. 作为罕见疾病的领导者, Alexion在推动eneoparatide的后期开发和全球商业化方面具有独特的优势, which has the potential to lessen the often debilitating impact of low parathyroid hormone and avoid the risks of high-dose calcium supplementation. 澳门葡京赌博游戏相信这个项目, 和Amolyt的天才团队一起, 专业知识和早期管道, 能让澳门葡京赌博游戏扩展到罕见的内分泌学吗.”

蒂埃里Abribat, 首席执行官, Amolyt制药, 他表示:“澳门葡京赌博游戏热烈欢迎澳门葡京网赌游戏拟议收购Amolyt, 一个与澳门葡京赌博游戏一样致力于为罕见疾病患者提供改变生活的治疗的组织. 该协议为澳门葡京赌博游戏有意义地推进管道疗法提供了机会. Strong Phase II data suggest eneboparatide has the potential to improve outcomes for patients and to shift the treatment paradigm for hypoparathyroidism, 澳门葡京赌博游戏期待着看到III期试验的持续推进.”

Eneboparatide is a PTH receptor 1 (PTHR1) agonist with a novel mechanism of action rationally designed to meet the therapeutic goals of hypoparathyroidism.⁴ Phase II data showed that eneboparatide achieved normalisation of serum calcium levels as well as the potential to eliminate dependence on daily calcium and vitamin D supplementation. 成人慢性甲状旁腺功能减退和高钙尿症, 结果显示依乙帕肽使尿钙正常. 除了, 甲状旁腺功能减退症, eneopaparte保存骨矿物质密度, 对骨质减少或骨质疏松风险增加的患者有重要的潜在益处.⁵

金融方面的考虑
根据协议条款, 澳门葡京网赌游戏将以最高1美元的总对价收购Amolyt制药的所有已发行股票.50亿美元，无现金和无债务. 这包括交易结束时的8亿美元预付款, plus the right for Amolyt制药’s shareholders to receive an additional contingent payment of $250 million payable upon achievement of a specified regulatory milestone.

以满足收购协议中惯常的成交条件为前提, 包括监管许可, 该交易预计将于2024年第三季度末完成.

笔记

Eneboparatide (azp - 3601)
Eneboparatide (azp - 3601) is an investigational therapeutic peptide designed to bind with high affinity to a specific conformation of the parathyroid hormone (PTH) receptor 1. 治疗目标包括:调节和维持血钙水平在正常范围内, and t在这里by managing the symptoms of hypoparathyroidism; limiting urine calcium excretion by restoring calcium reabsorption by the kidney; and potentially preventing progressive decline in kidney function and the 发展 of chronic kidney disease. Eneboparatide is also designed to have a short plasma half-life to potentially restore bone turnover to a more physiologic state and to help preserve bone integrity.

Hypoparathyroidism
Hypoparathyroidism is a rare condition defined by a deficiency of parathyroid hormone that results in decreased calcium and elevated phosphorus levels in the blood.¹ 大约占估计的115人的80%,在美国有1000人死亡，107人死亡,在欧盟，000名甲状旁腺功能减退症患者是女性.^2,3 尽管已有治疗方法, 患者经历持续的, life-altering symptoms and often develop complications and comorbidities that diminish quality of life and create segments of the patient population with specific clinical needs. 甲状旁腺功能减退症的临床表现影响许多组织和器官系统, 特别是, 肾脏和骨骼.^6,7

前瞻性陈述
本公告可能包含非历史事实陈述, 或"前瞻性陈述",，其中包括澳门葡京网赌游戏(澳门葡京网赌游戏)收购Amolyt制药的提议. 此类前瞻性陈述包括, 但不限于, 澳门葡京网赌游戏和Amolyt制药完成收购协议所设想的交易的能力, 包括双方满足收购协议中规定的条件的能力, 有关完成交易的预期时间表的陈述, 澳门葡京网赌游戏’s and Amolyt制药’s beliefs and expectations and statements about the benefits sought to be achieved in 澳门葡京网赌游戏’s proposed acquisition of Amolyt制药, 此次收购对澳门葡京网赌游戏和爱茉莉特制药的潜在影响, 收购协议终止的可能性, 以及依巴帕肽(AZP-3601)的预期益处和成功. These statements are based upon the current beliefs and expectations of 澳门葡京网赌游戏’s and Amolyt制药’s management and are subject to significant risks and uncertainties. T在这里 can be no guarantees that the conditions to the closing of the proposed transaction will be satisfied on the expected timetable or at all or that eneboparatide (AZP-3601) will receive the necessary regulatory approvals or prove to be commercially successful if approved. 如果基本假设被证明是不准确的，或者风险或不确定性成为现实, 实际结果可能与前瞻性陈述中所述的结果有重大差异. 风险和不确定性包括, 但不限于, uncertainties as to the timing of the acquisition;  the possibility that various conditions to the consummation of the acquisition contemplated by the acquisition agreement may not be satisfied or waived; the ability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing; the effects of disruption from the transactions contemplated by the acquisition agreement and the impact of the announcement and pendency of the transactions on Amolyt制药’s business; the risk that shareholder litigation in connection with the offer or the acquisition may result in significant costs of defence, indemnification and liability; the possibility that the achievement of the specified milestone described in the acquisition agreement may take longer to achieve than expected or may never be achieved and the resulting contingent milestone payment may never be realised; general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of COVID-19; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; competition from other products; and challenges in在这里nt in new product 发展, 包括获得监管部门的批准.

澳门葡京网赌游戏和Amolyt制药均不承担公开更新任何前瞻性声明的义务, 是否是新信息的结果, 未来事件或其他, 除非法律规定. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in 澳门葡京网赌游戏’s Annual Report on Form 20-F for the year ended 31 December 2023, 经随后提交给SEC的文件修订. 这些和其他澳门葡京网赌游戏向美国证券交易委员会提交的文件可在 www.证券交易委员会.政府.

Alexion
Alexion, 澳门葡京网赌游戏罕见病, 澳门葡京网赌游戏内部的团队专注于罕见疾病吗, 在2021年收购Alexion Pharmaceuticals后创建, 公司. 作为罕见病领域三十多年的领导者, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, 改变生活的药物的开发和商业化. Alexion的研究重点是包括补体级联在内的新分子和靶标, 以及血液学的发展, 肾脏学, 神经学, 代谢紊乱, 心脏病学和眼科. 总部设在波士顿, 麻萨诸塞州, Alexion在全球设有办事处，为70多个国家的患者提供服务.

澳门葡京网赌游戏
澳门葡京网赌游戏(LSE/STO/Nasdaq: AZN)是一家全球性制药公司, 以科学为主导的澳门葡京赌博游戏公司，专注于发现, 发展, 以及肿瘤学处方药的商业化, 罕见疾病, 和澳门葡京赌博游戏, 包括心血管, 肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门葡京网赌游戏在100多个国家开展业务，其创新药物被全球数百万患者使用. 请访问 澳门葡京网赌游戏.com 并在社交媒体上关注公司 @澳门葡京网赌游戏.

联系人

有关联络投资者关系组的详情，请按 在这里. 对于“媒体联系人”，单击 在这里.正文

参考文献

艾德里安·坎普
公司秘书
澳门葡京网赌游戏